These findings suggest that increased expression of TMED9 may inhibit the stemness characteristics of glioma cells, indicating that patients within the TMED9 low-expression group may exhibit heightened resistance to conventional anticancer treatments. Here, TMED9 is linked to central nervous system cancer.